title: [Multiple sclerosis: potential therapeutic options and update of ongoing studies].
abstract: The therapeutic options for the treatment of multiple sclerosis (MS) have experienced enormous progress over recent years. Despite these encouraging developments, available therapies are only partially effective, and the ultimate goal of curing MS is still far from being attained. The improved understanding of the cellular and molecular mechanisms of MS (immune) pathogenesis together with recent shifts in paradigms led to a variety of new therapeutic targets and approaches. In addition to modulation of the inflammatory process, therapeutic approaches focussing on active neuroprotection, remyelinization, and regeneration have become increasingly important. Based on current concepts of the MS pathogenesis, this article summarizes new therapeutic approaches. Substances and strategies currently tested in clinical trials are reviewed.
authors.affiliation: Abteilung für Allgemeine Neurologie und Hertie-Institut für Klinische Hirnforschung, Neurologische Klinik der Eberhard-Karls-Universität Tübingen. heinz.wiendl@uni-tuebingen.de
authors.forename: H
authors.initials: H
authors.lastname: Wiendl
authors.forename: H C
authors.initials: HC
authors.lastname: Lehmann
authors.forename: R
authors.initials: R
authors.lastname: Hohlfeld
authors.forename: H-P
authors.initials: HP
authors.lastname: Hartung
authors.forename: B C
authors.initials: BC
authors.lastname: Kieseier
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends*; D018450:Disease Progression; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010346:Patient Care Management / Q000379:methods* / Q000639:trends*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D018696:Neuroprotective Agents